Patent details

Basic Information

Publication number:

EP3166976

PCT Application Number:

CN2015083585

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP158195198

PCT Publication Number:

WO2016004876

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

French Title of Invention:

COMBINAISONS ANTI-PD-L1 POUR LE TRAITEMENT DES TUMEURS

German Title of Invention:

ANTI-PD-L1-KOMBINATIONEN ZUR TUMORBEHANDLUNG

SPC Number:

Dates

Filing date:

08/07/2015

Grant date:

23/02/2022

EP Publication Date:

17/05/2017

PCT Publication Date:

14/01/2016

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

23/02/2022

EP B1 Publication Date:

23/02/2022

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

08/07/2022

Expiration date:

08/07/2035

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

16/02/2022

 

 

Name:

Birdie Biopharmaceuticals Inc.

Address:

4th Floor, Harbour Place 103 South Church Street P.O. Box 10240, Grand Cayman, KY1-1002, Cayman Islands (KY)

Inventor

Name:

LI, Lixin

Address:

China (CN)

Priority

1

Priority Number:

201410325480

Priority Date:

09/07/2014

Priority Country:

China (CN)

2

Priority Number:

201410440824

Priority Date:

01/09/2014

Priority Country:

China (CN)

Classification

IPC classification:

A61K 31/4745; A61K 31/708; A61K 31/4375; A61K 47/50; A61K 45/00; A61P 35/00;

Publication

European Patent Bulletin

Issue number:

202208

Publication date:

23/02/2022

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages